ClinicalTrials.Veeva

Menu
T

Tan Tock Seng Hospital | Clinical Research and Innovation Office

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
ABT-494
Bevacizumab
BI 1015550
Nivolumab
Meropenem
Pembrolizumab
Filgotinib
Selpercatinib
Tenofovir Disoproxil Fumarate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

38 of 204 total trials

A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550 (FIBRONEER™-ON)

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1015550

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Venetoclax

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Sotorasib
Drug: Pembrolizumab

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Active, not recruiting
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)
Locations recently updated

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab an...

Enrolling
Carcinoma, Hepatocellular
Other: Placebo
Drug: Relatlimab

The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combinat...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Letrozole

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearr...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Selpercatinib

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling
Diffuse Large B-cell Lymphoma (DLBCL)
Drug: Doxorubicin
Drug: Prednisone/Prednisolone

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to w...

Enrolling
Chronic Kidney Disease
Drug: BAY3283142
Drug: Placebo

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called hu...

Enrolling
HER2 Mutation
Advanced Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Pembrolizumab

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment f...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo matching BI 1819479
Drug: BI 1819479

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can partici...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1839100
Drug: Placebo

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given i...

Enrolling
Non Small Cell Lung Cancer
Drug: Amivantamab
Drug: Lazertinib

Trial sponsors

T
N
Boehringer Ingelheim logo
AbbVie logo
N
Gilead Sciences logo
The University of Queensland logo
Bayer logo
Abbott logo
Boston Scientific logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems